Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 8853

Next Previous
Drug Profile

AZD 8853

Alternative Names: AZD-8853

Latest Information Update: 17 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Growth differentiation factor 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 06 Apr 2024 Efficacy, safety, pharmacokinetics and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 26 Jul 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (Parenteral) (before May 2023) (AstraZeneca Pipeline, May 2023)
  • 06 Jun 2023 AstraZeneca terminates phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US and Canada (Parenteral) in accordance to protocol Section 4.4, based on the overall risk-benefit profile observed to date (NCT05397171)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top